The menin inhibitor market is poised for rapid growth, with REVUFORJ setting the foundation and a strong pipeline of innovative, genetically targeted therapies on the horizon, including contributions from Asian developers like Japan's Sumitomo Pharma. With high levels of unmet need, particularly in NPM1-mutant and KMT2A-rearranged AML, this class is expected to play a critical role in the next g..